These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 20516242)

  • 1. LVH and hypertension: is treating the pressure not enough?
    Mandell BF
    Cleve Clin J Med; 2010 Jun; 77(6):344. PubMed ID: 20516242
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J; Delpón E; Valenzuela C
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of dietary sodium on the renin-angiotensin-aldosterone system and prevalence of left ventricular hypertrophy by EKG criteria.
    Williams JS; Williams GH; Jeunemaitre X; Hopkins PN; Conlin PR
    J Hum Hypertens; 2005 Feb; 19(2):133-8. PubMed ID: 15361890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of left ventricular hypertrophy: are there preferred drugs?
    Diamond JA; Phillips RA
    Curr Hypertens Rep; 2003 Oct; 5(5):368-71. PubMed ID: 12948428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke.
    Subramaniam V; Lip GY
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):703-13. PubMed ID: 19505285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of left ventricular hypertrophy in primary hypertension and therapeutic modification by antihypertensive drugs].
    Schiemann AL; Stimpel M
    Praxis (Bern 1994); 1997 Jul; 86(27-28):1101-6. PubMed ID: 9324718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
    Amabile G
    Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of left ventricular hypertrophy: hoping for a longer life.
    Sharp A; Mayet J
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):141-4. PubMed ID: 12563562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide.
    Lokhandwala Y; Damle A
    Curr Med Res Opin; 2004 May; 20(5):639-44. PubMed ID: 15140328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
    Verdecchia P; Angeli F; Pittavini L; Gattobigio R; Benemio G; Porcellati C
    Ital Heart J; 2004 Jul; 5(7):505-10. PubMed ID: 15487267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of left ventricular hypertrophy and improved prognosis: some hope now . . . or hype?
    Lip GY
    Circulation; 2001 Oct; 104(14):1582-4. PubMed ID: 11581130
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.